Torii Pharmaceutical Co., Ltd. (4551.T)
- Previous Close
6,340.00 - Open
6,340.00 - Bid 6,330.00 x --
- Ask 6,340.00 x --
- Day's Range
6,330.00 - 6,350.00 - 52 Week Range
3,105.00 - 6,350.00 - Volume
950,900 - Avg. Volume
204,579 - Market Cap (intraday)
177.944B - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
32.05 - EPS (TTM)
197.50 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield 120.00 (1.90%)
- Ex-Dividend Date Jun 27, 2025
- 1y Target Est
4,200.00
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; VTAMA cream, a topical treatment for atopic dermatitis and plaque psoriasis; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. It markets its products primarily through medical representatives for medical professionals. The company has a collaboration with ALK-Abelló A/S to develop and commercializes ALK's allergen immunotherapy drug targeting pollen diseases caused by grass pollen. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
www.torii.co.jp592
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4551.T
View MorePerformance Overview: 4551.T
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4551.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4551.T
View MoreValuation Measures
Market Cap
177.94B
Enterprise Value
135.08B
Trailing P/E
32.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.89
Price/Book (mrq)
1.47
Enterprise Value/Revenue
2.19
Enterprise Value/EBITDA
18.19
Financial Highlights
Profitability and Income Statement
Profit Margin
9.01%
Return on Assets (ttm)
3.30%
Return on Equity (ttm)
4.62%
Revenue (ttm)
61.66B
Net Income Avi to Common (ttm)
5.55B
Diluted EPS (ttm)
197.50
Balance Sheet and Cash Flow
Total Cash (mrq)
40.74B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--